Annora Pharma Private Limited Mesalamine Export Data — India (DGFT 2022–2026)

Name: Annora Pharma Private Limited Mesalamine Export Records India — #4 Exporter, 157 Shipments, $7.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Mesalamine

India Pharmaceutical Trade Intelligence

$1.3B103 Suppliers51 CountriesHS 30049099

ExportsIndia → UNITED STATES98.6%India → RUSSIA0.4%

ImportsUNITED STATES → India$1.0M ISRAEL → India$27.3K

#1 Supplier: ZYDUS LIFESCIENCES #1 Buyer: EVERSANA LIFE

Annora Pharma Private Limited — Mesalamine Exporter #4 | $7.8M Trade Value | TransData Nexus | TransData Nexus

Annora Pharma Private Limited — Mesalamine Exporter Profile

Indian Pharmaceutical Exporter · #4 for Mesalamine · $7.8M export value · DGFT Verified

Annora Pharma Private Limited is the #4 Indian exporter of Mesalamine with $7.8M in export value and 157 verified shipments. Annora Pharma Private Limited holds a 0.6% market share in Mesalamine exports across 1 countries. The company exports 13 pharmaceutical products worth $56.8M across 9 therapeutic categories.

Annora Pharma Private Limited — Mesalamine Export Profile: Buyers & Destinations

Annora Pharma Private Limited Mesalamine export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Mesalamine?

Country	Value	Shipments	Share
UNITED STATES	$43.8M	875	85.8%
RUSSIA	$1.9M	38	3.7%
MEXICO	$950.0K	19	1.9%
BRAZIL	$850.0K	17	1.7%

Who Are the Top Buyers of Mesalamine from India?

Buyer	Country	Value	Orders
EVERSANA LIFE SCIENCE SERVICES	UNITED STATES	$15.8M	317
NORTHSTAR DISTRIBUTION CENTER 8912	UNITED STATES	$3.1M	63
SUN PHARMACEUTICAL INDUSTRIES,INC.	UNITED STATES	$2.1M	42
SUN PHARMACEUTICAL INDUSTRIES INC	UNITED STATES	$1.9M	37
AO RANBAXY	RUSSIA	$1.2M	24
SUN PHARMACEUTICAL INDUSTRIES, INC.	UNITED STATES	$750.0K	15
AO "RANBAXY"	RUSSIA	$600.0K	12
EVERSANA LIFE SCIENCE SERVICES,	UNITED STATES	$200.0K	4
XXN PXXRMAXXUTIXXL IXXUSTXXES XXC	UNITED STATES	$150.0K	3
NORTHSTAR DISTRIBUTION CENTER	UNITED STATES	$150.0K	3

India's Mesalamine is purchased by 214 buyers worldwide. The top buyer is EVERSANA LIFE SCIENCE SERVICES (UNITED STATES), followed by NORTHSTAR DISTRIBUTION CENTER 8912 and SUN PHARMACEUTICAL INDUSTRIES,INC..

How Does Annora Pharma Private Limited Compare to Nearest Mesalamine Exporters?

Exporters ranked immediately above and below #4 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
1	ZYDUS LIFESCIENCES LIMITED	$19.3M	386	6	$50.0K
2	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$10.3M	207	11	$50.0K
4	ANNORA PHARMA PRIVATE LIMITED ★	$7.8M	157	1	$50.0K
8	ALKEM LABORATORIES LIMITED	$2.6M	52	1	$50.0K
9	ENCUBE ETHICALS PRIVATE LIMITED	$2.6M	80	1	$32.2K

Annora Pharma Private Limited ranks #4 among 103 Indian Mesalamine exporters. Average shipment value of $50.0K compared to the market average of $469.7K. The closest competitors by value are ZYDUS LIFESCIENCES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.

Which Indian Ports Ship Mesalamine Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	801	21.2%
SAHAR AIR	789	20.9%
DELHI AIR	494	13.1%
SAHAR AIR CARGO ACC (INBOM4)	415	11.0%
MUNDRA SEA	134	3.5%
Delhi Air	131	3.5%
Bombay Air	120	3.2%
NHAVA SHEVA SEA (INNSA1)	70	1.9%

Geopolitical & Trade Policy Impact on Annora Pharma Private Limited's Mesalamine Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Annora Pharma. The Israel-Iran conflict has led to disruptions in the Red Sea shipping routes, causing maritime carriers to suspend bookings and reroute vessels around the Cape of Good Hope. These changes have resulted in increased lead times and freight costs, disproportionately affecting time-sensitive pharmaceutical shipments. The Pharmaceutical Export Promotion Council of India (Pharmexcil) estimates potential losses ranging from ₹2,500 crore to ₹5,000 crore due to these disruptions. (fortuneindia.com)

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. With the U.S. imposing tariffs on Chinese goods, Indian exporters have an opportunity to capture a larger share of the American market. However, this advantage is tempered by the U.S. administration's pressure on pharmaceutical companies to lower drug prices and the potential for increased tariffs on imported pharmaceuticals, which could impact profit margins. (lemonde.fr)

In the European Union, the implementation of the Falsified Medicines Directive (FMD) has introduced stringent regulations aimed at preventing counterfeit drugs from entering the supply chain. Compliance with these regulations requires significant investment in serialization and traceability systems. For companies like Annora Pharma, adhering to these standards is crucial to maintain access to the lucrative EU market.

Annora Pharma Private Limited — Regulatory Compliance & Quality Standards

Regulatory compliance remains a critical factor for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA) has intensified inspections of Indian manufacturing facilities, with over 200 inspections conducted in 2023 and plans to increase this number in 2024. Non-compliance can lead to warning letters, import alerts, and bans, severely impacting export capabilities. (fact.net.in)

Annora Pharma's involvement in a patent infringement lawsuit with BioCryst Pharmaceuticals highlights the importance of navigating intellectual property rights carefully. Ensuring that generic products do not infringe on existing patents is essential to avoid legal disputes that can delay market entry and result in financial liabilities.

Maintaining high-quality standards and adhering to Good Manufacturing Practices (GMP) are imperative for sustaining credibility and competitiveness in international markets. Investing in robust quality control systems and staying abreast of evolving regulatory requirements will be key for Annora Pharma's continued success.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Mesalamine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Annora Pharma Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 51+ countries, 214+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Mesalamine

Mesalamine

Annora Pharma Private Limited — Mesalamine Exporter Profile

Annora Pharma Private Limited — Mesalamine Export Profile: Buyers & Destinations

Where Does India Export Mesalamine?

Who Are the Top Buyers of Mesalamine from India?

What Is India's Total Mesalamine Export Value and How Much Does Annora Pharma Private Limited Contribute?

What Is the Average Shipment Value for Annora Pharma Private Limited's Mesalamine Exports?

How Does Annora Pharma Private Limited Compare to Other Indian Mesalamine Exporters?

Regulatory Requirements: Exporting Mesalamine to Key Markets

United States — FDA

Mexico — COFEPRIS

How Does Annora Pharma Private Limited Compare to Nearest Mesalamine Exporters?

Which Indian Ports Ship Mesalamine Exports?

What Other Gastrointestinal Products Does Annora Pharma Private Limited Export?

Geopolitical & Trade Policy Impact on Annora Pharma Private Limited's Mesalamine Exports

Annora Pharma Private Limited — Regulatory Compliance & Quality Standards

About Annora Pharma Private Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Mesalamine Export Data from Annora Pharma Private Limited

Mesalamine Stats

Company Overview

Top Products by Annora Pharma Private Limited

Related Analysis

Need Detailed Export Data?

Data Source